At the news
? BEARISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 16:46 ET
Spyre Therapeutics announced a $300 million public offering of common stock, with underwriters expected to receive a 30-day option to purchase up to an additional $45 million in shares. The proceeds will be used for general corporate purposes, including funding clinical development programs in IBD and immune-mediated diseases.
- Spyre Therapeutics is conducting a $300 million public offering of common stock.
- Underwriters are expected to receive a 30-day option to purchase up to an additional $45 million in shares.
- All shares are being sold by the company, indicating primary issuance and dilution to existing shareholders.
- Proceeds will support clinical development and general corporate purposes.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access